{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,5]],"date-time":"2026-08-05T00:58:17Z","timestamp":1785891497811,"version":"3.56.0"},"reference-count":59,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2006,6,30]],"date-time":"2006-06-30T00:00:00Z","timestamp":1151625600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Psychopharmacology"],"published-print":{"date-parts":[[2006,9]]},"DOI":"10.1007\/s00213-006-0437-9","type":"journal-article","created":{"date-parts":[[2006,6,29]],"date-time":"2006-06-29T20:40:44Z","timestamp":1151613644000},"page":"415-423","source":"Crossref","is-referenced-by-count":105,"title":["Evaluation of antipsychotic drugs as inhibitors of multidrug resistance transporter P-glycoprotein"],"prefix":"10.1007","volume":"187","author":[{"given":"Jun-Sheng","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hao-Jie","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John S.","family":"Markowitz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer L.","family":"Donovan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C. Lindsay","family":"DeVane","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2006,6,30]]},"reference":[{"key":"437_CR1","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1111\/j.1365-2362.1987.tb01246.x","volume":"17","author":"B Angelin","year":"1987","unstructured":"Angelin B, Arvidsson A, Dahlqvist R, Hedman A, Schenck-Gustafsson K (1987) Quinidine reduces biliary clearance of digoxin in man. Eur J Clin Invest 17:262\u2013265","journal-title":"Eur J Clin Invest"},{"key":"437_CR2","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1007\/s00213-001-0933-x","volume":"159","author":"M Aravagiri","year":"2002","unstructured":"Aravagiri M, Marder SR (2002) Brain, plasma and tissue pharmacokinetics of risperidone and 9-hydroxyrisperidone after separate oral administration to rats. Psychopharmacology (Berl) 159:424\u2013431","journal-title":"Psychopharmacology (Berl)"},{"key":"437_CR3","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1055\/s-2007-979308","volume":"31","author":"M Aravagiri","year":"1998","unstructured":"Aravagiri M, Marder SR, Wirshing D, Wirshing WC (1998) Plasma concentrations of risperidone and its 9-hydroxy metabolite and their relationship to dose in schizophrenic patients: simultaneous determination by a high performance liquid chromatography with electrochemical detection. Pharmacopsychiatry 31:102\u2013109","journal-title":"Pharmacopsychiatry"},{"key":"437_CR4","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1002\/1099-081X(199911)20:8<369::AID-BDD200>3.0.CO;2-6","volume":"20","author":"M Aravagiri","year":"1999","unstructured":"Aravagiri M, Teper Y, Marder SR (1999) Pharmacokinetics and tissue distribution of olanzapine in rats. Biopharm Drug Dispos 20:369\u2013377","journal-title":"Biopharm Drug Dispos"},{"key":"437_CR5","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1080\/00498250110060969","volume":"31","author":"A Ayrton","year":"2001","unstructured":"Ayrton A, Morgan P (2001) Role of transport proteins in drug absorption, distribution and excretion. Xenobiotica 31:469\u2013497","journal-title":"Xenobiotica"},{"key":"437_CR6","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1007\/s11095-004-9016-0","volume":"22","author":"CJ Bachmeier","year":"2005","unstructured":"Bachmeier CJ, Miller DW (2005) A fluorometric screening assay for drug efflux transporter activity in the blood\u2013brain barrier. Pharm Res 22:113\u2013121","journal-title":"Pharm Res"},{"key":"437_CR7","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/S0024-3205(02)01680-6","volume":"71","author":"DW Boulton","year":"2002","unstructured":"Boulton DW, DeVane CL, Liston HL, Markowitz JS (2002) In vitro P-glycoprotein affinity for atypical and conventional antipsychotics. Life Sci 71:163\u2013169","journal-title":"Life Sci"},{"key":"437_CR8","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1176\/appi.ajp.158.987.971-a","volume":"158","author":"RA Bressan","year":"2001","unstructured":"Bressan RA, Jones HM, Ell PJ, Pilowsky LS (2001) Dopamine D(2) receptor blockade in schizophrenia. Am J Psychiatry 158:971\u2013972","journal-title":"Am J Psychiatry"},{"key":"437_CR9","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1176\/appi.ajp.161.4.700","volume":"161","author":"F Centorrino","year":"2004","unstructured":"Centorrino F, Goren JL, Hennen J, Salvatore P, Kelleher JP, Baldessarini RJ (2004) Multiple versus single antipsychotic agents for hospitalized psychiatric patients: case-control study of risks versus benefits. Am J Psychiatry 161:700\u2013706","journal-title":"Am J Psychiatry"},{"key":"437_CR10","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1093\/schbul\/23.4.663","volume":"23","author":"RR Conley","year":"1997","unstructured":"Conley RR, Buchanan RW (1997) Evaluation of treatment-resistant schizophrenia. Schizophr Bull 23:663\u2013674","journal-title":"Schizophr Bull"},{"key":"437_CR11","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1111\/j.1365-2125.1980.tb01070.x","volume":"9","author":"R Dahlqvist","year":"1980","unstructured":"Dahlqvist R, Ejvinsson G, Schenck-Gustafsson K (1980) Effect of quinidine on plasma concentration and renal clearance of digoxin. A clinically important drug interaction. Br J Clin Pharmacol 9:413\u2013418","journal-title":"Br J Clin Pharmacol"},{"key":"437_CR12","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1097\/00004714-200108000-00008","volume":"21","author":"CL DeVane","year":"2001","unstructured":"DeVane CL, Nemeroff CB (2001) An evaluation of risperidone drug interactions. J Clin Psychopharmacol 21:408\u2013416","journal-title":"J Clin Psychopharmacol"},{"key":"437_CR13","doi-asserted-by":"crossref","first-page":"1501","DOI":"10.1046\/j.1528-1157.2001.12301.x","volume":"42","author":"SM Dombrowski","year":"2001","unstructured":"Dombrowski SM, Desai SY, Marroni M, Cucullo L, Goodrich K, Bingaman W, Mayberg MR, Bengez L, Janigro D (2001) Overexpression of multiple drug resistance genes in endothelial cells from patients with refractory epilepsy. Epilepsia 42:1501\u20131506","journal-title":"Epilepsia"},{"key":"437_CR14","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1211\/0022357043969","volume":"56","author":"AA Ela El","year":"2004","unstructured":"El Ela AA, Hartter S, Schmitt U, Hiemke C, Spahn-Langguth H, Langguth P (2004) Identification of P-glycoprotein substrates and inhibitors among psychoactive compounds\u2014implications for pharmacokinetics of selected substrates. J Pharm Pharmacol 56:967\u2013975","journal-title":"J Pharm Pharmacol"},{"key":"437_CR15","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1093\/schbul\/22.1.15","volume":"22","author":"SM Essock","year":"1996","unstructured":"Essock SM, Hargreaves WA, Dohm FA, Goethe J, Carver L, Hipshman L (1996) Clozapine eligibility among state hospital patients. Schizophr Bull 22:15\u201325","journal-title":"Schizophr Bull"},{"key":"437_CR16","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1200\/JCO.2000.18.5.1124","volume":"18","author":"PM Fracasso","year":"2000","unstructured":"Fracasso PM, Westervelt P, Fears CL, Rosen DM, Zuhowski EG, Cazenave LA, Litchman M, Egorin MJ (2000) Phase I study of paclitaxel in combination with a multidrug resistance modulator, PSC 833 (Valspodar), in refractory malignancies. J Clin Oncol 18:1124\u20131134","journal-title":"J Clin Oncol"},{"key":"437_CR17","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1097\/00007691-200404000-00012","volume":"26","author":"C Hiemke","year":"2004","unstructured":"Hiemke C, Dragicevic A, Grunder G, Hatter S, Sachse J, Vernaleken I, Muller MJ (2004) Therapeutic monitoring of new antipsychotic drugs. Ther Drug Monit 26:156\u2013160","journal-title":"Ther Drug Monit"},{"key":"437_CR18","doi-asserted-by":"crossref","first-page":"3473","DOI":"10.1073\/pnas.97.7.3473","volume":"97","author":"S Hoffmeyer","year":"2000","unstructured":"Hoffmeyer S, Burk O, von Richter O, Arnold HP, Brockmoller J, Johne A, Cascorbi I, Gerloff T, Roots I, Eichelbaum M, Brinkmann U (2000) Functional polymorphisms of the human multidrug-resistance gene: multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo. Proc Natl Acad Sci U S A 97:3473\u20133478","journal-title":"Proc Natl Acad Sci U S A"},{"key":"437_CR19","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1093\/jat\/28.4.264","volume":"28","author":"J Hopenwasser","year":"2004","unstructured":"Hopenwasser J, Mozayani A, Danielson TJ, Harbin J, Narula HS, Posey DH, Shrode PW, Wilson SK, Li R, Sanchez LA (2004) Postmortem distribution of the novel antipsychotic drug quetiapine. J Anal Toxicol 28:264\u2013267","journal-title":"J Anal Toxicol"},{"key":"437_CR20","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1097\/00007691-199712000-00001","volume":"19","author":"KM Jalava","year":"1997","unstructured":"Jalava KM, Partanen J, Neuvonen PJ (1997) Itraconazole decreases renal clearance of digoxin. Ther Drug Monit 19:609\u2013613","journal-title":"Ther Drug Monit"},{"key":"437_CR21","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1176\/ps.46.8.801","volume":"46","author":"MG Juarez-Reyes","year":"1995","unstructured":"Juarez-Reyes MG, Shumway M, Battle C, Bacchetti P, Hansen MS, Hargreaves WA (1995) Effects of stringent criteria on eligibility for clozapine among public mental health clients. Psychiatr Serv 46:801\u2013806","journal-title":"Psychiatr Serv"},{"key":"437_CR22","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1248\/bpb.28.316","volume":"28","author":"M Kageyama","year":"2005","unstructured":"Kageyama M, Namiki H, Fukushima H, Ito Y, Shibata N, Takada K (2005) In vivo effects of cyclosporin A and ketoconazole on the pharmacokinetics of representative substrates for P-glycoprotein and cytochrome P450 (CYP) 3A in rats. Biol Pharm Bull 28:316\u2013322","journal-title":"Biol Pharm Bull"},{"key":"437_CR23","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1016\/S0006-3223(01)01251-3","volume":"50","author":"S Kapur","year":"2001","unstructured":"Kapur S, Remington G (2001) Dopamine D(2) receptors and their role in atypical antipsychotic action: still necessary and may even be sufficient. Biol Psychiatry 50:873\u2013883","journal-title":"Biol Psychiatry"},{"key":"437_CR24","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1176\/ajp.156.2.286","volume":"156","author":"S Kapur","year":"1999","unstructured":"Kapur S, Zipursky RB, Remington G (1999) Clinical and theoretical implications of 5-HT2 and D2 receptor occupancy of clozapine, risperidone, and olanzapine in schizophrenia. Am J Psychiatry 156:286\u2013293","journal-title":"Am J Psychiatry"},{"key":"437_CR25","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1046\/j.1440-1614.1999.00639.x","volume":"33","author":"NA Keks","year":"1999","unstructured":"Keks NA, Altson K, Hope J, Krapivensky N, Culhane C, Tanaghow A, Doherty P, Bootle A (1999) Use of antipsychosis and adjunctive medications by an inner urban community psychiatric service. Aust N Z J Psychiatry 33:896\u2013901","journal-title":"Aust N Z J Psychiatry"},{"key":"437_CR26","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1124\/jpet.301.1.7","volume":"301","author":"W Loscher","year":"2002","unstructured":"Loscher W, Potschka H (2002) Role of multidrug transporters in pharmacoresistance to antiepileptic drugs. J Pharmacol Exp Ther 301:7\u201314","journal-title":"J Pharmacol Exp Ther"},{"key":"437_CR27","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1124\/jpet.102.039255","volume":"303","author":"KM Mahar Doan","year":"2002","unstructured":"Mahar Doan KM, Humphreys JE, Webster LO, Wring SA, Shampine LJ, Serabjit-Singh CJ, Adkison KK, Polli JW (2002) Passive permeability and P-glycoprotein-mediated efflux differentiate central nervous system (CNS) and non-CNS marketed drugs. J Pharmacol Exp Ther 303:1029\u20131037","journal-title":"J Pharmacol Exp Ther"},{"key":"437_CR28","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/j.jconrel.2005.06.006","volume":"107","author":"K Manjunath","year":"2005","unstructured":"Manjunath K, Venkateswarlu V (2005) Pharmacokinetics, tissue distribution and bioavailability of clozapine solid lipid nanoparticles after intravenous and intraduodenal administration. J Control Release 107:215\u2013228","journal-title":"J Control Release"},{"issue":"2","key":"437_CR29","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1177\/0091270005283839","volume":"46","author":"JS Markowitz","year":"2006","unstructured":"Markowitz JS, DeVane CL, Malcolm RJ, Gefroh HA, Wang JS, Zhu HJ, Donovan JL (2006) Pharmacokinetics of olanzapine after single-dose oral administration of standard tablet versus normal and sublingual administration of an orally disintegrating tablet in normal volunteers. J Clin Pharmacol 46(2):164\u2013171","journal-title":"J Clin Pharmacol"},{"key":"437_CR30","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1093\/schbul\/18.3.515","volume":"18","author":"HY Meltzer","year":"1992","unstructured":"Meltzer HY (1992) Treatment of the neuroleptic\u2013nonresponsive schizophrenic patient. Schizophr Bull 18:515\u2013542","journal-title":"Schizophr Bull"},{"key":"437_CR31","first-page":"443","volume":"36","author":"H Miyazaki","year":"1986","unstructured":"Miyazaki H, Matsunaga Y, Nambu K, Oh-e Y, Yoshida K, Hashimoto M (1986) Disposition and metabolism of [14C]-haloperidol in rats. Arzneimittelforschung 36:443\u2013452","journal-title":"Arzneimittelforschung"},{"key":"437_CR32","volume-title":"Clark\u2019s analysis of drugs and poisons, vol. 2","author":"AC Moffat","year":"2004","unstructured":"Moffat AC, Osselton MD, Widdop B (2004) Clark\u2019s analysis of drugs and poisons, vol. 2. Pharmaceutical Press, London"},{"key":"437_CR33","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1007\/s002130050020","volume":"148","author":"S Nyberg","year":"2000","unstructured":"Nyberg S, Farde L (2000) Non-equipotent doses partly explain differences among antipsychotics\u2014implications of PET studies. Psychopharmacology (Berl) 148:22\u201323","journal-title":"Psychopharmacology (Berl)"},{"key":"437_CR34","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1111\/j.1600-0773.1996.tb00273.x","volume":"79","author":"J Partanen","year":"1996","unstructured":"Partanen J, Jalava KM, Neuvonen PJ (1996) Itraconazole increases serum digoxin concentration. Pharmacol Toxicol 79:274\u2013276","journal-title":"Pharmacol Toxicol"},{"key":"437_CR35","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1007\/BF00543791","volume":"25","author":"KE Pedersen","year":"1983","unstructured":"Pedersen KE, Thayssen P, Klitgaard NA, Christiansen BD, Nielsen-Kudsk F (1983a) Influence of verapamil on the inotropism and pharmacokinetics of digoxin. Eur J Clin Pharmacol 25:199\u2013206","journal-title":"Eur J Clin Pharmacol"},{"key":"437_CR36","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1007\/BF00613925","volume":"24","author":"KE Pedersen","year":"1983","unstructured":"Pedersen KE, Christiansen BD, Klitgaard NA, Nielsen-Kudsk F (1983b) Effect of quinidine on digoxin bioavailability. Eur J Clin Pharmacol 24:41\u201347","journal-title":"Eur J Clin Pharmacol"},{"key":"437_CR37","first-page":"99","volume":"28","author":"TI Prior","year":"2003","unstructured":"Prior TI, Baker GB (2003) Interactions between the cytochrome P450 system and the second-generation antipsychotics. J Psychiatry Neurosci 28:99\u2013112","journal-title":"J Psychiatry Neurosci"},{"key":"437_CR38","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/S0920-1211(98)00106-5","volume":"34","author":"G Regesta","year":"1999","unstructured":"Regesta G, Tanganelli P (1999) Clinical aspects and biological bases of drug-resistant epilepsies. Epilepsy Res 34:109\u2013122","journal-title":"Epilepsy Res"},{"key":"437_CR39","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1038\/316817a0","volume":"316","author":"JR Riordan","year":"1985","unstructured":"Riordan JR, Deuchars K, Kartner N, Alon N, Trent J, Ling V (1985) Amplification of P-glycoprotein genes in multidrug-resistant mammalian cell lines. Nature 316:817\u2013819","journal-title":"Nature"},{"key":"437_CR40","doi-asserted-by":"crossref","first-page":"4538","DOI":"10.1073\/pnas.83.12.4538","volume":"83","author":"IB Roninson","year":"1986","unstructured":"Roninson IB, Chin JE, Choi KG, Gros P, Housman DE, Fojo A, Shen DW, Gottesman MM, Pastan I (1986) Isolation of human mdr DNA sequences amplified in multidrug-resistant KB carcinoma cells. Proc Natl Acad Sci USA 83:4538\u20134542","journal-title":"Proc Natl Acad Sci USA"},{"key":"437_CR41","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1067\/mcp.2000.109156","volume":"68","author":"AJ Sadeque","year":"2000","unstructured":"Sadeque AJ, Wandel C, He H, Shah S, Wood AJ (2000) Increased drug delivery to the brain by P-glycoprotein inhibition. Clin Pharmacol Ther 68:231\u2013237","journal-title":"Clin Pharmacol Ther"},{"key":"437_CR42","doi-asserted-by":"crossref","first-page":"2517","DOI":"10.1172\/JCI118699","volume":"97","author":"AH Schinkel","year":"1996","unstructured":"Schinkel AH, Wagenaar E, Mol CA, van Deemter L (1996) P-glycoprotein in the blood-brain barrier of mice influences the brain penetration and pharmocological activity of many drugs. J Clin Invest 97:2517\u20132524","journal-title":"J Clin Invest"},{"issue":"1","key":"437_CR43","first-page":"41","volume":"7","author":"G Sedvall","year":"1992","unstructured":"Sedvall G (1992) The current status of PET scanning with respect to schizophrenia. Neuropsychopharmacology 7(1):41\u201354 (Aug)","journal-title":"Neuropsychopharmacology"},{"key":"437_CR44","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1111\/j.2042-7158.1995.tb06741.x","volume":"47","author":"GP Sgaragli","year":"1995","unstructured":"Sgaragli GP, Valoti M, Palmi M, Frosini M, Giovannini MG, Bianchi L, Della Corte L (1995) Rat tissue concentrations of chlorimipramine, chlorpromazine and their N-demethylated metabolites after a single oral dose of the parent compounds. J Pharm Pharmacol 47:782\u2013790","journal-title":"J Pharm Pharmacol"},{"key":"437_CR45","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1097\/00004714-199706000-00010","volume":"17","author":"GM Simpson","year":"1997","unstructured":"Simpson GM, Lindenmayer JP (1997) Extrapyramidal symptoms in patients treated with RSP. J Clin Psychopharmacol 17:194\u2013201","journal-title":"J Clin Psychopharmacol"},{"issue":"16","key":"437_CR46","doi-asserted-by":"crossref","first-page":"3437","DOI":"10.1097\/00001756-199911080-00032","volume":"10","author":"SM Sisodiya","year":"1999","unstructured":"Sisodiya SM, Heffernan J, Squier MV (1999) Over-expression of P-glycoprotein in malformations of cortical development. Neuroreport 10(16):3437\u20133441","journal-title":"Neuroreport"},{"key":"437_CR47","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/S0140-6736(00)03573-X","volume":"357","author":"SM Sisodiya","year":"2001","unstructured":"Sisodiya SM, Lin WR, Squier MV, Thom M (2001) Multidrug-resistance protein 1 in focal cortical dysplasia. Lancet 357:42\u201343","journal-title":"Lancet"},{"issue":"Pt 1","key":"437_CR48","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1093\/brain\/awf002","volume":"125","author":"SM Sisodiya","year":"2002","unstructured":"Sisodiya SM, Lin WR, Harding BN, Squier MV, Thom M (2002) Drug resistance in epilepsy: expression of drug resistance proteins in common causes of refractory epilepsy. Brain 125(Pt 1):22\u201331","journal-title":"Brain"},{"key":"437_CR49","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1016\/S0022-3565(24)37590-1","volume":"286","author":"JW Smit","year":"1998","unstructured":"Smit JW, Weert B, Schinkel AH, Meijer DK (1998) Heterologous expression of various P-glycoproteins in polarized epithelial cells induces directional transport of small (type 1) and bulky (type 2) cationic drugs. J Pharmacol Exp Ther 286:321\u2013327","journal-title":"J Pharmacol Exp Ther"},{"key":"437_CR50","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1097\/00007691-200108000-00007","volume":"23","author":"Y Suzuki","year":"2001","unstructured":"Suzuki Y, Someya T, Shimoda K, Hirokane G, Morita S, Yokono A, Inoue Y, Takahashi S (2001) Importance of the cytochrome P450 2D6 genotype for the drug metabolic interaction between chlorpromazine and haloperidol. Ther Drug Monit 23:363\u2013368","journal-title":"Ther Drug Monit"},{"key":"437_CR51","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1177\/106002800303700202","volume":"37","author":"H Tanaka","year":"2003","unstructured":"Tanaka H, Matsumoto K, Ueno K, Kodama M, Yoneda K, Katayama Y, Miyatake K (2003) Effect of clarithromycin on steady-state digoxin concentrations. Ann Pharmacother 37:178\u2013181","journal-title":"Ann Pharmacother"},{"key":"437_CR52","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/j.1528-1157.1995.tb01657.x","volume":"36","author":"DM Tishler","year":"1995","unstructured":"Tishler DM, Weinberg KI, Hinton DR, Barbaro N, Annett GM, Raffel C (1995) MDR1 gene expression in brain of patients with medically intractable epilepsy. Epilepsia 36:1\u20136","journal-title":"Epilepsia"},{"key":"437_CR53","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1006\/phrs.1999.0535","volume":"40","author":"M Verschraagen","year":"1999","unstructured":"Verschraagen M, Koks CH, Schellens JH, Beijnen JH (1999) P-glycoprotein system as a determinant of drug interactions: the case of digoxin-verapamil. Pharmacol Res 40:301\u2013306","journal-title":"Pharmacol Res"},{"key":"437_CR54","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1016\/j.pnpbp.2005.06.019","volume":"30","author":"N Yasui-Furukori","year":"2006","unstructured":"Yasui-Furukori N, Saito M, Nakagami T, Kaneda A, Tateishi T, Kaneko S (2006) Association between multidrug resistance 1 (MDR1) gene polymorphisms and therapeutic response to bromperidol in schizophrenic patients: a preliminary study. Prog Neuropsychopharmacol Biol Psychiatry 30:286\u2013291","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"key":"437_CR55","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1111\/j.1365-2125.2003.02061.x","volume":"57","author":"N Yasui-Furukori","year":"2004","unstructured":"Yasui-Furukori N, Mihara K, Takahata T, Suzuki A, Nakagami T, De Vries R, Tateishi T, Kondo T, Kaneko S (2004) Effects of various factors on steady-state plasma concentrations of risperidone and 9-hydroxyrisperidone: lack of impact of MDR-1 genotypes. Br J Clin Pharmacol 57:569\u2013575","journal-title":"Br J Clin Pharmacol"},{"key":"437_CR56","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1017\/S1461145704004390","volume":"7","author":"JS Wang","year":"2004","unstructured":"Wang JS, Ruan Y, Taylor RM, Donovan JL, Markowitz JS, DeVane CL (2004a) The brain entry of risperidone and 9-hydroxyrisperidone are greatly limited by P-glycoprotein. Int J Neuropsychopharmacology 7:415\u2013419","journal-title":"Int J Neuropsychopharmacology"},{"key":"437_CR57","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1038\/sj.npp.1300372","volume":"29","author":"JS Wang","year":"2004","unstructured":"Wang JS, Taylor R, Runa Y, Donovan LJ, Markowitz SJ, DeVane CL (2004b) Olanzapine penetration into brain is greater in transgenic mdr1a p-glycoprotein deficient mice than FVB1 (wild-type) aminals. Neuropsychopharmacology 29:551\u2013557","journal-title":"Neuropsychopharmacology"},{"key":"437_CR58","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1124\/dmd.30.6.631","volume":"30","author":"X Wen","year":"2002","unstructured":"Wen X, Wang JS, Bckman JT, Laitila J, Neuvonen PJ (2002) Trimethoprim and sulfamethoxazole are selective inhibitors of CYP2C8 and CYP2C9, respectively. Drug Metab Dispos 30:631\u2013635","journal-title":"Drug Metab Dispos"},{"key":"437_CR59","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1007\/BF00315316","volume":"45","author":"PK Yeung","year":"1993","unstructured":"Yeung PK, Hubbard JW, Korchinski ED, Midha KK (1993) Pharmacokinetics of chlorpromazine and key metabolites. Eur J Clin Pharmacol 45:563\u2013569","journal-title":"Eur J Clin Pharmacol"}],"container-title":["Psychopharmacology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00213-006-0437-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00213-006-0437-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00213-006-0437-9","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,9]],"date-time":"2025-01-09T16:42:26Z","timestamp":1736440946000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00213-006-0437-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,6,30]]},"references-count":59,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2006,9]]}},"alternative-id":["437"],"URL":"https:\/\/doi.org\/10.1007\/s00213-006-0437-9","relation":{},"ISSN":["0033-3158","1432-2072"],"issn-type":[{"value":"0033-3158","type":"print"},{"value":"1432-2072","type":"electronic"}],"subject":[],"published":{"date-parts":[[2006,6,30]]}}}